Income Tax - Deferred Tax Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024
Deferred tax assets:
Net operating loss carryforwards	$ 28,914,050	$ 31,759,300
R&D credit carryforwards	3,830,306	408,500
Stock based compensation	2,799,908	2,850,300
Lease liability	2,951,877	2,651,200
Deferred revenue	6,307
Capitalized Section 174 R&D costs	7,481,832	8,025,800
Net unrealized built-in losses (NUBIL) - Section 382		1,175,900
Other	319,826	378,500
Unrealized gains/losses	507,547	6,800
Deferred tax assets	46,811,653	47,256,300
Deferred tax liabilities:
Property, plant and equipment, primarily due to differences in depreciation	(738,290)	(665,200)
Right-of-use lease assets	(5,573,944)	(4,659,300)
Deferred tax liabilities	(6,312,234)	(5,324,500)
Valuation allowance	(40,499,419)	$ (41,931,800)
Change in gross unrecognized tax positions
Gross increases for tax positions related to the acquisition of Elusys Therapeutics	1,480,974
Divestiture of equity interests in Elusys Therapeutics	$ (1,480,974)